EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 168 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $7,000 | 0.0% | 113 | -7.4% | 0.00% | – |
| Q3 2019 | $7,000 | +250.0% | 122 | +190.5% | 0.00% | – |
| Q2 2019 | $2,000 | 0.0% | 42 | 0.0% | 0.00% | – |
| Q1 2019 | $2,000 | -33.3% | 42 | -44.0% | 0.00% | – |
| Q4 2018 | $3,000 | -70.0% | 75 | -47.2% | 0.00% | – |
| Q3 2018 | $10,000 | -94.4% | 142 | -95.8% | 0.00% | -100.0% |
| Q2 2018 | $178,000 | 0.0% | 3,399 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $178,000 | -0.6% | 3,399 | +1.5% | 0.00% | 0.0% |
| Q4 2017 | $179,000 | -11.8% | 3,349 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $203,000 | -22.2% | 3,349 | +0.9% | 0.00% | -33.3% |
| Q2 2017 | $261,000 | -4.7% | 3,318 | +0.5% | 0.00% | 0.0% |
| Q1 2017 | $274,000 | +4.6% | 3,300 | 0.0% | 0.00% | -25.0% |
| Q4 2016 | $262,000 | +13.4% | 3,300 | 0.0% | 0.00% | +33.3% |
| Q3 2016 | $231,000 | +75.0% | 3,300 | -1.5% | 0.00% | +50.0% |
| Q2 2016 | $132,000 | +6500.0% | 3,350 | +6600.0% | 0.00% | – |
| Q1 2016 | $2,000 | -50.0% | 50 | 0.0% | 0.00% | – |
| Q4 2015 | $4,000 | -87.9% | 50 | -87.7% | 0.00% | -100.0% |
| Q2 2015 | $33,000 | – | 405 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |